Athena Diagnostics, Inc.

Biorasi is a customer-focused, full-service, contract research organization (CRO) that leverages speed and agility in the execution of clinical trials to maximize speed-to-market for its sponsors – all powered by our proprietary TALOS™ project management system.

Biorasi is a leader in neurology, nephrology, dermatology, oncology, and the emerging digital therapeutics market. It is our mission to be a catalyst for growth, innovation, and evolution in the field of clinical research – moving the industry forward while improving results for our partners and outcomes for their patients. Our culture is based on our strong commitment to building true partnerships with our sponsors. We approach all of our trials with urgency, commitment, and resolve.

Established in 2002, Biorasi is headquartered in Aventura, FL, with office-based teams around the globe. From its regional presences, Biorasi is able to directly support studies in the Americas, Europe, and APAC. We have received multiple accolades including placement in the INC 500 and 5000 list of fastest-growing companies in America, Frost and Sullivan’s Entrepreneurial Company of the Year for the CRO Industry, and the CRO Leadership Award from Life Science Leader magazine.

Mission
Diablo Clinical Research is committed to advancing health through medical research and community service.



History
Diablo Clinical Research, established by Dr. Weinstein in 1995, has conducted over 600 studies with thousands of patients. Today our database is comprised of over 12,000 patients who have either completed a study with us, are currently enrolled in a study, or have expressed interest in future clinical study participation.

Our Founder and Medical Director Richard L. Weinstein, MD a board certified endocrinologist and internist has practiced medicine in the San Francisco Bay Area for 30 years.

In 2005 Leonard Chuck, PhD, MD and a practicing internist in our local community for over 20 years joined Diablo Clinical Research as an Investigator. In 2007 Mark Christiansen, MD, who practiced and conducted research in the community for over 17 years, also joined Diablo Clinical Research as an Investigator. Both Dr. Chuck and Dr. Christiansen became Co-Medical Directors of our facility in 2008.

Diablo Clinical Research specializes in clinical research. We have been working in our Walnut Creek location for over 17 years. We have 6 MDs on staff with specialties in endocrinology, internal medicine, cardiology, and neurology.

VetPharm, Inc. is a full-service contract research organization (CRO) dedicated exclusively to animal health. It offers a complete menu of pilot/pivotal/post-marketing clinical trial support services, including protocol development, data form design, investigator recruitment, site qualification, enrollment enhancement, study administration, ICH-GCP training, site monitoring, data management, statistical analysis, medical writing, and regulatory support to pharmaceutical, biotechnical, nutraceutical, nutrition, and device companies in the United States and Europe. VetPharm employs a comprehensive study management system and a consortium of study-ready investigators which facilitate rapid study initiation, accelerated enrollment, and superior results to meet sponsors'​ critical timelines.

VetPharm has broad clinical trial experience across all therapeutic areas which enables it to undertake virtually any trial and complete it quickly, efficiently, and accurately. VetPharm's investigator consortium includes board-certified specialists in the following disciplines: Behavior, Cardiology, Dentistry, Dermatology, Endocrinology, Gastroenterology, Immunology, Internal Medicine, Neurology, Oncology, Ophthalmology, Radiology, Surgery, Theriogenology, and Urology.

Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognosis and precise treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts.

Founded in 2002, CELPROGEN is a biotechnology company, with over 5000 products in the market, focused on developing stem cell research and therapeutics products for regenerative medicine in cardiology, oncology, diabetes & neurology. All of Celprogen’s biological products, including stem cells, cancer stem cells, iPC’s & media with specific ECM’s, are manufactured and produced in the United States of America.

CELPROGEN provides novel molecular diagnostics and therapeutic product development solutions for Biotechnology, Pharmaceutical, In-vitro diagnostics and academic partnership for drug discovery.

It has 3 divisions:

• Therapeutic Division: Focused on Drug Discovery efforts to develop Pharmaceutical agents and Drugs in the following categories: Cardiovascular, Diabetes, Neurological, Oncology,Renal and Metabolic disorders.
• Life Science Division: Provides research tools & solutions for assays, enzymes, antibodies, antigens, stem cells, Tissue culture expansion and differentiation media, primary and established cell cultures, tumor markers, cardiac markers, proteomic and genomic reagents and assay systems for life science academic and pharmaceutical communities.
• Device Division: Provides novel ELISA based assay, protein array, DNA array and cellular based assay systems that are cost effective for Research and In-vitro diagnostics Industries.